Open AccessP1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL‐LIKE DIFFUSE LARGE B‐CELL LYMPHOMA (ABC‐DLBCL): A COST EFFECTIVENESS ANALYSIS
Author(s) -
Rho H.,
Jeong I. J.H.,
Prica A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000849780.37760.ca
Subject(s) - ibrutinib , medicine , diffuse large b cell lymphoma , febrile neutropenia , oncology , population , rituximab , lymphoma , neutropenia , surgery , leukemia , chronic lymphocytic leukemia , chemotherapy , environmental health